Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.23
+0.56500.87%
Post-market: 65.230.00000.00%16:13 EDT
Volume:2.29M
Turnover:150.12M
Market Cap:12.61B
PE:172.12
High:66.30
Open:65.95
Low:64.33
Close:64.67
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.46
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.99
PE(LYR):36.24

Loading ...

GUIDANCE: (BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Adjusted EPS Range $4.90 - $5.10, vs. FactSet Est of $4.94

MT Newswires Live
·
Aug 07

BioMarin Q2 GAAP Net Income Drops 81% to $45 Million; Revenue Rises 20% to $990 Million

Reuters
·
Aug 07

BioMarin Q2 Revenue Beats Estimates; Raises 2026 Outlook

Reuters
·
Aug 07

Biomarin Pharmaceutical Q2 Adj. EPS $1.20 Beats $0.69 Estimate, Sales $990.000M Beat $926.908M Estimate

Benzinga Earnings
·
Aug 07

Biomarin Pharmaceutical Outlook FY Adjusted EPS USD 4.9-5.1

THOMSON REUTERS
·
Aug 07

Biomarin Pharmaceutical Outlook FY Revenue USD 3,875-3,925 Million

THOMSON REUTERS
·
Aug 07

Biomarin Pharmaceutical Inc Fy2026 Shr View $3.64, REV View $3.87 Bln

THOMSON REUTERS
·
Aug 07

Biomarin Pharmaceutical Q2 EPS USD 0.23

THOMSON REUTERS
·
Aug 07

BioMarin Pharmaceutical Inc Expected to Post Earnings of 69 Cents a Share - Earnings Preview

Reuters
·
Aug 05

Spruce Biosciences Names Jessica Cohen Pfeffer Vice President, Clinical Development

Reuters
·
Aug 03

BioMarin Schedules Q2 2026 Results Conference Call and Webcast

Reuters
·
Jul 30

Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 28

BioMarin and n-Lorem Foundation enter research collaboration in ReNU syndrome

TIPRANKS
·
Jul 27

Biomarin Pharmaceutical - and N-Lorem Announce Global Exclusive License to Develop Aso Medicine for Renu Syndrome

THOMSON REUTERS
·
Jul 27

BioMarin, n-Lorem Partner to Develop Antisense Drug Candidate for ReNU Syndrome

Reuters
·
Jul 27

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

Reuters
·
Jul 27

Biomarin Pharmaceutical is Maintained at Buy by Citigroup

Dow Jones
·
Jul 17

FDA Accepts Biomarin Voxzogo Full-approval Application for Children with Achondroplasia

Reuters
·
Jul 13

U.S. Food and Drug Administration Accepts Biomarin's Supplemental New Drug Application for Full Approval of Voxzogo® (vosoritide) for Children with Achondroplasia

THOMSON REUTERS
·
Jul 13

Biomarin Pharmaceutical - FDA Sets Pdufa Target Action Date of Feb. 28, 2027 for Voxzogo Snda

THOMSON REUTERS
·
Jul 13